Mayo Clinic
Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Amyloidosis
What is new in Amyloidosis research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- AcoramidisPhase 3 · NCT06563895
- Acoramidis (AG10)Phase 3 · NCT04988386 · NCT07116473
- ALXN2220Phase 3 · NCT07213583 · NCT06183931
- BortezomibPhase 3 · NCT07224672 · NCT07901725 · NCT04754945 · NCT05250973 · NCT06022939 · NCT07388602 · NCT07793422 · NCT06342466
- CAEL-101Phase 3 · NCT04504825 · NCT04512235
- CyclophosphamidePhase 3 · NCT07224672 · NCT07901725 · NCT04754945 · NCT05250973 · NCT06022939 · NCT07388602 · NCT07793422
- cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimenPhase 3 · NCT04504825 · NCT04512235
- Dara-CyBorDPhase 3 · NCT07709715
- DaratumumabPhase 3 · NCT07901725 · NCT07335887 · NCT06768489 · NCT05250973 · NCT03346135 · NCT05898646 · NCT07793422
- Daratumumab and Hyaluronidase-fihjPhase 3 · NCT07110844 · NCT06022939
- DexamethasonePhase 3 · NCT04270175 · NCT07224672 · NCT07901725 · NCT07335887 · NCT04847453 · NCT04754945 · NCT05250973 · NCT06022939 · NCT07388602 · NCT03618537 · NCT07793422 · NCT06342466 · NCT06629818
- EplontersenPhase 3 · NCT05667493
- EtentamigPhase 3 · NCT07793422
- LinvoseltamabPhase 3 · NCT07901725 · NCT06292780
- MelphalanPhase 3 · NCT02909036 · NCT03346135 · NCT06022939
- nexiguran ziclumeranPhase 3 · NCT06672237
- NNC6019-0001Phase 3 · NCT07207811 · NCT06260709
- NTLA-2001Phase 3 · NCT06128629
- NucresiranPhase 3 · NCT07052903 · NCT07223203
- NXC-201Phase 3 · NCT07709715
- Sacubitril / ValsartanPhase 3 · NCT06712030
- SCTC21CPhase 3 · NCT07388602
- VutrisiranPhase 3 · NCT06679946 · NCT07223203 · NCT04153149
- anti-BCMA/CD3 bispecific antibodyPhase 2 · NCT07151690
- AT02Phase 2 · NCT05951049
- BCMA bispecificPhase 2 · NCT07524634
- Belantamab mafodotinPhase 2 · NCT07224672
- Cancer Therapeutic ProcedurePhase 2 · NCT07285044
- CM336 Injection(High dose group)Phase 2 · NCT07039578
- CM336 Injection(Low dose group)Phase 2 · NCT07039578
- DapagliflozinPhase 2 · NCT06420167
- Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous)Phase 2 · NCT06629818
- Daratumumab SCPhase 2 · NCT04270175
- DaraVRD/DaraVCDPhase 2 · NCT04991103
- Dexamethasone OralPhase 2 · NCT05996406
- Eque-cel CAR-T TherapyPhase 2 · NCT07055724
- HBI0101 CARTPhase 2 · NCT06971380
- IxazomibPhase 2 · NCT05451771 · NCT03618537
- PomalidomidePhase 2 · NCT04270175 · NCT05451771 · NCT06768489 · NCT06342466
- QLS4131Phase 2 · NCT07751471
- SiltuximabPhase 2 · NCT03315026
- sonrotoclaxPhase 2 · NCT07335887 · NCT07687004
- TeclistamabPhase 2 · NCT07110844 · NCT07638683 · NCT06649695
- Teclistamab (Tec)Phase 2 · NCT07079423 · NCT06935162
- TrimetazidinePhase 2 · NCT07836699
- VenetoclaxPhase 2 · NCT05996406 · NCT04847453 · NCT06629818
- XDdPhase 2 · NCT07743957
- ABBV-383 (Etentamig)Phase 1/2 · NCT06158854
- AZD0120Phase 1/2 · NCT07081646
- Belantamab mafodotin 1.0 mg/kg (12 weeks)Phase 1/2 · NCT05145816
- Belantamab mafodotin 1.4 mg/kg (12 weeks)Phase 1/2 · NCT05145816
- Belantamab mafodotin 1.9 mg/kg (12 weeks)Phase 1/2 · NCT05145816
- Belantamab mafodotin 1.9 mg/kg (8 weeks)Phase 1/2 · NCT05145816
- Belantamab mafodotin 2.5 mg/kg (8 weeks)Phase 1/2 · NCT05145816
- Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosagesPhase 1/2 · NCT05145816
- BendamustinePhase 1/2 · NCT05451771
- CM336 (BCMA/CD3 bispecific antibody)Phase 1/2 · NCT07687004
- Daratumumab InjectionPhase 1/2 · NCT05451771
- Dexamethasone Oral, 10 mgPhase 1/2 · NCT05451771
- Dexamethasone Oral, 20 mgPhase 1/2 · NCT05451771
- DobutrexPhase 1/2 · NCT06318260
- ElranatamabPhase 1/2 · NCT06569147
- FISH assayPhase 1/2 · NCT05451771
- FKC289 infusionPhase 1/2 · NCT07765524
- NXC-201 CAR-TPhase 1/2 · NCT06097832
- TQB2934 injectionPhase 1/2 · NCT07266116
- Venetoclax MTD with DexamethasonePhase 1/2 · NCT05451771
- Venetoclax Oral Tablet, 200 mgPhase 1/2 · NCT05451771
- Venetoclax Oral Tablet, 400 mgPhase 1/2 · NCT05451771
- CoramitugPhase 1 · NCT07448623
- GC012F InjectionPhase 1 · NCT07250269
- GPRC5D CARTPhase 1 · NCT07874334
- IsatuximabPhase 1 · NCT04754945
- Ixazomib CitratePhase 1 · NCT04847453
- JNJ-79635322Phase 1 · NCT05652335 · NCT06768489
- LenalidomidePhase 1 · NCT06768489
- PegfilgrastimPhase 1 · NCT02909036
- AnselamimabEarly phase 1 · NCT07615270
- Metabolically Armed BCMA CAR-T cells.Early phase 1 · NCT07085559
- YOLT-201Early phase 1 · NCT06082050
Closest to patients
- [64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid CardiomyopathyPhase 3 trial: AmyloidosisBrigham and Women's Hospital · Boston, United StatesPhase 3Results expected 2027
- Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection FractionPhase 3 trial: Sacubitril / ValsartanBellvitge University Hospital · L'hospitalet De Llobregat, Spain + 8 more hospitalsPhase 3Results expected 2027
- TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With PolyneuropathyPhase 3 trial: Nucresiran, VutrisiranUniversity General Hospital of Heraklion · Heraklion, Greece + 57 more hospitalsPhase 3Results expected 2027
Choose one to continue
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Closing the Diagnostic Gap in Transthyretin Amyloid Cardiomyopathy.
Closing the Diagnostic Gap in Transthyretin Amyloid Cardiomyopathy.
Journal of the American Heart Association
PubMed · PMID 42980515Publication
The Effectiveness of Teclistamab in Patients With Relapsed/Refractory Light Chain Amyloidosis: A Multicenter Retrospective Study.
The Effectiveness of Teclistamab in Patients With Relapsed/Refractory Light Chain Amyloidosis: A Multicenter Retrospective Study.
British journal of hospital medicine (London, England : 2005)
PubMed · PMID 42980103Review
[Diagnosis of amyloidosis].
[Diagnosis of amyloidosis].
Therapeutische Umschau. Revue therapeutique
PubMed · PMID 42979799Case report
When rare meets routine: A case report of amyloid light-chain amyloidosis with multiorgan involvement in primary care.
When rare meets routine: A case report of amyloid light-chain amyloidosis with multiorgan involvement in primary care.
Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia
PubMed · PMID 42985369
Organisations that can help
Helplines, patient groups and support services for you and your family.
Select your country to see the organisations there, starting with the ones closest to you.
Umbrella organisations (they connect national groups)
Amyloidosis Alliance
Global alliance of amyloidosis patient groups: advocacy, awareness and earlier diagnosis, access to care, patient involvement in research, World Amyloidosis Day, resource library and toolkit.
Visit site: Amyloidosis Alliance
EURORDIS – Rare Diseases Europe
Alliance of over 1,000 rare disease patient organisations, with a list of rare disease helplines by country.
Visit site: EURORDIS – Rare Diseases Europe
Myeloma Patients Europe (MPE)
European umbrella of myeloma patient groups, with a list of members by country.
Visit site: Myeloma Patients Europe (MPE)
General support
For anyone who is ill, whatever the disease: patients' rights and legal aid, crisis lines, hospice and palliative care, care in another EU country, and patient organisations' umbrella bodies.
International
European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
Visit site: European Patients' Forum (EPF)
International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Visit site: International Alliance of Patients' Organizations
Frontlight is not affiliated with these organisations; we list them because they help.
Checked automatically every 90 days.
Find fellow researchers
Groups with active Amyloidosis work.
University College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Columbia University Irving Medical Center
New York, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Cleveland Clinic
Cleveland, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Boston University
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
The Royal Free Hospital
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Brigham and Women's Hospital
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Stanford University
Stanford, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Policlinico San Matteo Fondazione
Pavia, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
Boston Medical Center
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it